Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Ruanne Barnabas grew up in Durban, South Africa, during a time of “deep inequity in health, opportunity, and justice”.

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...

Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with the disease in 2023, Florida data show. That’s followed by St. Lucie County ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

To put this spike into perspective, the rural city of around 32,000 people has now recorded more HIV cases in two years than ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...